SLC5A2 and lupus nephritis: They found that those treated with SGLT2 inhibitors had a lower risk of developing lupus nephritis (HR, 0.55; 95% CI, 0.40–0.77), requiring dialysis (HR, 0.29; 95% CI, 0.17–0.48), requiring kidney transplantation (HR, 0.14; 95% CI, 0.03–0.62), or experiencing heart failure (HR, 0.65; 95% CI, 0.53–0.78), or all-cause mortality (HR, 0.35; 95% CI, 0.26–0.47).